COMPASS Pathways plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMPS research report →
Range $13 – $25
Price Chart
About the company
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy.
- CEO
- Kabir Kumar Nath
- IPO
- 2020
- Employees
- 156
- HQ
- London, CH, GB
Get TickerSpark's AI analysis on CMPS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.10B
- P/E
- -2.06
- Fwd P/E
- 41.48
- PEG
- 0.03
- P/S
- 0.00
- P/B
- 8.45
- EV/EBITDA
- -3.13
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -212.85%
- ROIC
- -99.30%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-179,037,000
- Net Income
- $-287,862,000-85.6%
- EPS
- $-3.08-33.9%
- OCF Growth
- -31.9%
- FCF Growth
- -31.9%
- 52W High
- $15.87
- 52W Low
- $4.88
- 50D MA
- $11.42
- 200D MA
- $10.52
- Beta
- 2.41
- RSI (14)
- 36
- Avg Volume
- 3.03M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Compass said it is on track to finish the COMP360 NDA in the next two weeks and is positioning for a potentially rapid FDA decision and a first-half 2027 launch in TRD.· November 3, 2026
- NDA submission for COMP360 is expected to be completed in the next two weeks, with FDA interactions described as productive and “constructive.”
- Management said the National Priority Voucher creates the potential for a 30-60 day FDA review, though they stressed timing remains uncertain.
- Commercial launch preparation is well underway, with all planned non-field commercial roles filled and hiring focused on the field force.
- Management highlighted strong market research: 95% of surveyed TRD patients said they are constantly struggling, and about 90% of interventional psychiatrists said they would prescribe COMP360 within the first year.
- Balance sheet remains solid, with $444 million of cash on hand as of September 30th, which management said should fund operations through launch and into 2028.
Compass did not report revenue or EPS on this call. The company said it had $444 million of cash on hand as of September 30th. Management said the COMP360 NDA will be completed in the next two weeks, with a potential FDA review window of one to two months under the National Priority Voucher, and they continue to expect a launch in the first half of 2027. They also reiterated that the PTSD study is actively enrolling and that the company is exploring additional label-expansion opportunities.
Kabir Nath framed the quarter around regulatory execution and launch readiness rather than financial performance. He emphasized that COMP360 is differentiated by rapid onset within 24 hours, durability that could last up to 12 months, and a generally well-tolerated safety profile. His tone was confident and forward-leaning, with repeated emphasis on high-quality data, a strong patent position, and the possibility of a very rapid approval.
The CFO did not provide a separate prepared financial update on the call, so the discussion of financials was limited. The main hard figure cited was the $444 million of cash on hand as of September 30th, which management said should carry the company through launch and into 2028. Management also emphasized the cost and complexity of building REMS and launch infrastructure, but did not give updated operating expense, burn, margin, or capital allocation figures.
Analysts focused on timing risk, rescheduling, launch logistics, and competitive positioning. Management said the National Priority Voucher suggests a one-to-two-month FDA review, but noted that DEA rescheduling and state-level rescheduling are separate steps that add uncertainty. On access and commercialization, they said CPT Category III-to-Category I coding could take 12-18 months, but patient support programs should limit affordability barriers at launch, and they described REMS/training/logistics as resource-intensive but manageable with the infrastructure they are building.
The bull case from this call is that COMP360 appears to have a differentiated clinical and commercial profile: rapid onset, long durability, infrequent dosing, and strong prescriber interest. Management also believes the company has enough cash, manufacturing/commercial readiness, and site infrastructure to support a 2027 launch if approval comes through quickly.
The biggest risks discussed were regulatory and implementation timing: FDA review, DEA rescheduling, and state rescheduling all have to line up before patients can be treated. Launch execution also depends on complex REMS, coding, reimbursement, and site training, while management acknowledged that broader competitive dynamics and later label-expansion opportunities are still uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.1%
- Shares Outstanding
- 140.71M
- Float Shares
- 139.40M
of shares held by institutions
242 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Deep Track Capital, LP | 12.16M | 0 |
| Rtw Investments, LP | 10.70M | ▲ 68.58K |
| Bit Capital Gmbh | 8.97M | ▲ 2.62M |
| Tang Capital Management LLC | 5.00M | ▲ 997.80K |
| Ark Investment Management LLC | 4.91M | ▲ 1.45M |
| Two Sigma Investments, LP | 4.47M | ▲ 1.89M |
| Ubs Group AG | 3.12M | ▲ 1.64M |
| Point72 Asset Management, L.P. | 2.62M | ▲ 2.62M |
| Logos Global Management LP | 2.25M | ▲ 2.25M |
| Eagle Health Investments LP | 2.06M | 0 |
| Bank Of America Corp | 2.02M | ▲ 1.99M |
| Dafna Capital Management LLC | 2.01M | ▼ 406.93K |
Held by 39 ETFs
Biggest fund positions in CMPS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 3, 26 | Nath Kabir | other | 5,962 |
| May 27, 26 | Karydas Daphne | other | 21,110 |
| May 27, 26 | SANTINI GINO | other | 30,158 |
| May 27, 26 | Gover Justin D. | other | 21,110 |
| May 27, 26 | JONAS JEFFREY M | other | 21,110 |
| May 27, 26 | Riley Wayne Joseph | other | 21,110 |
| May 27, 26 | McQuade Robert | other | 21,110 |
| May 27, 26 | Norton David Y | other | 21,110 |
| May 27, 26 | Tregoning Kathleen | other | 41,119 |
| May 27, 26 | Tregoning Kathleen | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CMPS coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CMPS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 1
businesswire.com · Nov 19
Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch
marketbeat.com · Nov 12
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
businesswire.com · Nov 11
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
businesswire.com · Nov 9
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 5
Compass Pathways Q3 Earnings Call Highlights
defenseworld.net · Nov 5
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
businesswire.com · Nov 4
Compass Pathways: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
